New Lynx Dx Urine Test Outperforms MRI in Identifying Prostate Cancer Upgrading During Active Surveillance

Clinical Validation Study Supports a Non-Invasive Monitoring Approach Where MPS2-AS Accurately Guides the Need for Surveillance Biopsies ANN ARBOR, Mich., May 5, 2026 /PRNewswire/ -- Lynx Dx, a leader in innovative diagnostic solutions, announced today the validation of MyProstateScore...